Copyright © 2024 Research Nester. All Rights Reserved
Acute Hepatic Porphyria Treatment Market size was valued at USD 4.23 billion in 2024 and is likely to cross USD 8.08 billion by 2037, expanding at more than 5.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of acute hepatic porphyria treatment is assessed at USD 4.41 billion.
The acute hepatic porphyria treatment market is thriving on the back of growing awareness among the people regarding this disease coupled with the growing research activities.
Growth Drivers
Increasing Prevalence of Rare Metabolic and Genetic Disease to Boost the Market Growth
Since the incidence rate of rare metabolic disorders such as acute hepatic porphyria have been growing in the past few year, the demand for acute hepatic porphyria treatment is increasing. According to U.S. National Library of Medicines (Genetic Home Reference), the prevalence of porphyria ranges from 1 in 500 to 1 in 50,000 people worldwide and acute intermittent porphyria (AIP) is the most common form of acute hepatic porphyria in most countries. This is anticipated to significantly expand the acute hepatic porphyria treatment market.
Expanding Healthcare R&D and Increase in Awareness to Drive the Market Growth
The expanding growth in pharmaceutical as well as biotechnology industries all over the world is improving at a fast pace owing to the increasing number of cases of various diseases. Further, there is an increased awareness among people regarding acute hepatic porphyria owing to the fact that it primarily affects the nervous system and other major organs. The growing research and development for better treatment methods at research laboratories further fuels the healthcare industry. On the back of these, the market is predicted to grow over the forecast period.
Challenges
High Treatment Costs and Lack of Reimbursement Facilities to Hamper the Market Growth
Despite the improving healthcare infrastructure, there is a high cost associated with this drug used for the treatment of this disease. In addition to this, the poor reimbursement policies in the developing countries is estimated to hinder the growth of acute hepatic porphyria treatment market in the future.
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.1% |
|
Base Year Market Size (2024) |
USD 4.23 billion |
|
Forecast Year Market Size (2037) |
USD 8.08 billion |
|
Regional Scope |
|
The acute hepatic porphyria treatment market is segmented by product type, by application and by end user. The application segment is further segmented into hospitals, pharmacies, clinics and others. Based on this, the segment for hospitals is anticipated to hold the leading share in the market on account of availability of porphyria medicines used for the patient’s treatment only at the hospital under the doctors’ supervision.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Application |
|
|
By End User |
|
On the basis of regional analysis, the acute hepatic porphyria treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market for acute hepatic porphyria treatment in North America industry is anticipated to hold largest revenue share by 2037, driven by presence of leading players in the region. which manufacture and market acute hepatic porphyria treatment. Moreover, support from government in implementation of advanced healthcare technologies coupled with the rise in patients with genetic metabolic disorders in the region further increases the product demand. The market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of rise in awareness about this rare disorder along with the growing research activities in the region. The developing economies in the region, especially the countries such as China, India and Japan further provide significant opportunities to raise the demand for acute hepatic porphyria treatment.
The acute hepatic porphyria treatment market is dominated by market players such as Abbott Ltd. and Recordati Rare Diseases Inc. Moreover, several players in the pharmaceutical industry are increasingly expanding their product diversification by utilizing advanced healthcare technologies to develop treatment that would be suitable for all patients without causing any adverse side-effects on them. Additionally, market players are also hugely investing on research and developmental activities that would focus on treatment of rare diseases with the help of advancement in healthcare technologies.
Abbott Ltd.,
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?